Batlevi, C. L., Park, S. I., Nastoupil, L., Phillips, T., Amengual, J. E., Andorsky, D., Campbell, P., McKay, P., Pagel, J. M., Leonard, J. P., Yang, J., O’Connor, H., Hamlett, A., Adib, D., & Morschhauser, F. (2021). Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma. Blood, 138(Supplement 1), 2207–2207. https://doi.org/10.1182/blood-2021-148199